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ABSTRACT Binding of the Fc portion of IgG coated on targets to Fc receptors (e.g., CD16) expressed on leukocytes (i.e.,
2D binding) is an initiating step for immune responses such as phagocytosis or antibody-dependent cellular cytotoxicity. In
vivo, circulating leukocytes are exposed to plasma IgG. The competition from soluble IgG (i.e., 3D binding) may affect the 2D
binding. Many cell surface receptors, CD16 included, have soluble counterparts. While their physiological significance is not
clear, receptor-based competitive inhibition therapy, in which soluble receptors, ligands, and their analogs are employed to
compete with surface-bound receptors and ligands to prevent unwanted adhesion, is widely used to treat various diseases.
To provide a quantitative basis for design of these therapeutic approaches, we developed a mathematical model for 2D and
3D competition binding. The model relates cell-surface adhesion (in the presence and absence of dislodging forces) to the
concentration of the soluble competitor, the densities of the surface-bound receptors and ligands, as well as the binding
affinities of the 2D and 3D interactions. Binding of CD16-expressing cells to an IgG-coated surface in the presence of a
soluble competitor (IgG or anti-CD16 antibody) was quantified by a centrifugation assay. The agreement between experiment
and theory supports the validity of the model, which could be useful in predicting the efficacy of the competitor.
INTRODUCTION
Cells communicate with the extracellular environment
through their surface receptors. Some receptors interact with
surface-bound ligands, such as adhesion proteins and extra-
cellular matrix components. Others bind soluble ligands,
such as cytokines and growth factors. In addition, many
receptors exist in both surface-bound and soluble forms,
produced by alternative splicing of the transcripts or by
proteolysis of the membrane receptors. For example, CD16,
the Fc receptor III (FcRIII) expressed on the surface of
various leukocytes, also exists in circulation (Mathiot et al.,
1993). P-selectin, an adhesion receptor for leukocytes ex-
pressed on activated platelets and endothelial cells, is also
present in the plasma of normal subjects and elevated in
patients with thrombotic disorders (Dunlop et al., 1992;
Katayama et al., 1993; Ushiyama et al., 1993; Chong et al.,
1994). The physiological significance of such a coexistence
of both forms is not fully understood. In many cases, how-
ever, soluble receptors have been suggested to play an
integral part in the dynamic interaction between their mem-
brane-bound counterparts and ligands (Heaney and Golde,
1998).
Similarly, many ligands are present in both forms. Anti-
bodies, which are secreted by B cells as soluble molecules,
become surface-bound ligands for the Fc receptors upon
binding to antigens deposited on a surface. In a recent work,
the immunoglobulin G (IgG) in human sera was shown to
inhibit partially or completely the binding of a monoclonal
antibody (mAb) 3G8 to CD16a on the surface of monocytes
and natural killer (NK) cells (Edberg and Kimberly, 1997).
Because 3G8 could effectively block CD16/IgG interaction
in cell adhesion experiments, a physiological role for
plasma IgG in the competitive inhibition of the binding of
cell surface CD16 to immobilized IgG was suggested.
Receptor-based competitive inhibition is an appealing
therapeutic strategy that holds promise for the treatment of
a wide variety of diseases related to the dysfunction of cell
adhesion (Crandall et al., 1993; Martin et al., 1993; Jameson
and Bevan, 1995; Kalinke et al., 1996). The idea is to use
soluble receptors, ligands, or their analogs to competitively
inhibit the unwanted adhesion mediated by surface-linked
receptors and ligands. For example, immune thrombocyto-
penic purpura (ITP) is an autoimmune disease that produces
autoantibodies against platelets. Adhesion via Fc receptors
triggers leukocytes to clear the opsonized platelets. For
patients who do not respond to conventional therapy, a high
dose of intravenous IgG (Wallace et al., 1997) or anti-FcR
monoclonal antibodies (mAbs) (Clarkson et al., 1986), both
of which competitively block the leukocyte Fc receptors,
may be life saving. Other examples include the use of
gp120-binding domain mimics to block HIV binding to
CD4 receptors on T cells (Capon et al., 1989). Also, argi-
nine-glycine-aspartic acid (RGD)-containing peptides have
been used to inhibit the binding of integrin IIb3 in throm-
bosis (Kotze et al., 1995) and to block integrin v3-
mediated adhesion in osteoporosis (Dresner-Pollak and
Rosenblatt, 1994; Chorev et al., 1995).
Thus, not only do both surface-bound and soluble recep-
tors and ligands commonly coexist under physiological
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conditions, but soluble molecules also have been widely
used in receptor-based competitive inhibition therapy. In
this paper, the adhesive interaction between two surface-
bound molecules is referred to as two-dimensional (2D)
binding. In comparison, binding of a soluble ligand to a cell
surface receptor is called three-dimensional (3D) interaction
(Piper et al., 1998). Despite its importance, no mathematical
model exists in the literature to describe the competition
between 2D and 3D bindings. The present paper describes
one such model. This model is useful in assessing whether
a naturally existing soluble receptor is able to competitively
inhibit the binding of its cell-bound counterpart under phys-
iological conditions. Moreover, the model allows for de-
tailed quantitative analysis of the receptor-based competi-
tive inhibition therapy.
The present 2D/3D competition model is an extension of
the well-known theory of 3D/3D competition between two
soluble ligands (Cheng and Prusoff, 1973). Because we are
interested in cell adhesion mediated by a small number of
receptor/ligand bonds under the influence of applied forces,
the extension includes two aspects. First, the deterministic
formulation of reaction kinetics has been replaced by a
probabilistic equivalence, i.e., the master equations (Mc-
Quarrie, 1963). Thus we are concerned with the probability
of having bonds instead of the (average) density of bonds.
Second, not only has one of the binding affinities of the two
competitors been changed from 3D to 2D, but it also has
become a function of force instead of merely a constant.
Both aspects are key elements of a recently developed
model for 2D receptor/ligand binding in cell adhesion (Piper
et al., 1998). The new addition in the present model is the
inclusion of a 3D competitor in the binding scheme.
Our theoretical model was tested experimentally, using a
centrifugation assay (McClay et al., 1981), and was found to
be consistent with the data. While this is similar to our
previous work (Piper et al., 1998), the present experiment
added a new variable—the soluble competitor. Instead of
the E-selectin/carbohydrate ligand system used in our ear-
lier work, the present study employed the CD16/IgG sys-
tem. CD16 is a 50–80-kDa low-affinity leukocyte receptor
for the Fc portion of IgG (FcRIII) (Hibbs et al., 1989;
Scallon et al., 1989; Selvaraj et al., 1989). Binding of CD16
to aggregated IgG triggers a variety of immune responses,
including receptor-mediated phagocytosis, antibody-depen-
dent cellular cytotoxicity, and release of inflammatory me-
diators (Lanier et al., 1989; Letourneur et al., 1991; O’Shea
et al., 1991; Nagarajan et al., 1995). Our experiment quan-
tified adhesions of CD16-expressing cells to surface-bound
IgG in the presence of either a similar (IgG) or dissimilar
(anti-CD16 mAb) competitor in solution. This design was
chosen for its physiological relevance, as it represents an in
vitro model for ITP and other autoimmune diseases involv-
ing leukocyte FcRs and deposited immune complexes. The
similar competitor experiment mimics the treatment of ITP
with high doses of intravenous IgG (Wallace et al., 1997) as
well as other situations in which soluble molecules compete
with their surface-bound counterparts. The dissimilar com-
petitor experiment mimics the treatment of ITP with anti-
FcR mAbs (Clarkson et al., 1986) as well as other situa-
tions in which high-affinity analogs or mAbs are employed
for receptor-based competitive inhibition therapy.
The formula of Cheng and Prusoff (1973) for 3D/3D
competition provides the basis for a method of measuring
binding affinity too low to be directly measured by the
Scatchard analysis (Scatchard, 1949). Similarly, our 2D/3D
competition model can be used to measure affinities of the
respective surface-bound and soluble ligands when com-
bined with a quantitative assay for cell adhesion, such as the
centrifugation assay (Piper et al., 1998). The efficacy of a
soluble competitor is usually measured by a phenomeno-
logical index, IC50 (i.e., the concentration required to inhibit
adhesion by 50%). Such a definition is adapted from the
convention of the 3D/3D competition (Cheng and Prusoff,
1973), where IC50 is a function of the affinities of the ligand
and its competitor as well as concentrations for all reactive
species. For the case of 2D/3D competition, IC50 also de-
pends on an additional variable, the dislodging force applied
to remove the less adherent cells, as one might expect.
While the exact mathematical relationship between IC50 and
these parameters is fairly complex, a useful result derived
from the present work is that IC50 is approximately equal to
the dissociation constant of the 3D competitor when adhe-
sion is sufficiently low. Another simple approximate equa-
tion relates the competitor concentration required to inhibit
adhesion to a low level (say, 20%) to the receptor and
ligand densities, as well as the 2D and 3D affinities. This
formula may be used to guide the dosage in competitive
inhibition therapy.
THEORETICAL DEVELOPMENT
Governing equations
The reaction in question is
R CL|;
kf,3D
kr,3D
B3D outside contact area (1a)
2R L CL|;
kf,2D , kf,3D
kr,2D , kr,3D
B2D B3D inside contact area
(1b)
where R, L, C, and B denote, respectively, receptor, ligand,
soluble competitor, and bond. The subscript in B indicates
whether the bond is 2D (i.e., between two surface-bound
molecules) or 3D (i.e., between a surface-linked molecule
and a soluble competitor). The forward and reverse rates, kf
and kr, are also given a 2D or 3D designation. Traditionally,
the kinetics of reaction Eq. 1a is described by
dB3D
dt  kf,3DRC kr,3DB3D (2a)
where t is time and the square brackets denote concentra-
tions. Such a deterministic kinetic equation assumes a large
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system of reactive molecules. This is usually true outside
the contact area between the cell and the substrate surface.
Inside the contact area Ac, however, the system is small and
the stochastic characteristics of binding become apparent
(Piper et al., 1998; Chesla et al., 1998; Long et al., 1999).
The master equations are required to describe the probabi-
listic kinetics of the reaction in Eq. 1b:
dpnm
dt  kf,2D
(n) mlAcmr m n 1pn1m  kr,2D(n1)n 1pn1m
 kf,3DcAcmr m 1 npnm1
 kr,3Dm 1pnm1
 kf,2D(n1) mlAcmr m n kr,2D(n) n
 kf,3DcAcmr m n kr,3Dm]pnm (2b)
where pnm is the probability of having m 3D bonds and n 2D
bonds within Ac. mr and ml are the respective total densities
of receptors and ligands. c is the concentration of the soluble
competitor. In addition to the Markovian process and se-
quential binding assumptions that underlie the master equa-
tions (McQuarrie, 1963), it is further assumed that ml and c
are much greater than the respective density and concentra-
tion of the 2D and 3D bonds. These are valid assumptions
in the centrifugation experiment (Piper et al., 1998).
In contrast to the constant 3D rates, the 2D rates depend
on the force applied to the cell and the number of 2D bonds
sharing that force, as indicated by the superscript n. For the
present work that only deals with the steady state, it is
sufficient to express such a dependency in a constitutive
equation for the 2D affinity:
Ka,2D fn – kf,2D
(n)
kr,2D(n)
 Ka,2D0 exp afnkBT (3)
where a is a bond parameter, kB is the Boltzmann constant,
and T is the absolute temperature. Among the several mod-
els proposed for the dependence of 2D affinity on dislodg-
ing force, Eq. 3 was chosen for its simplicity. It has been
shown to be an appropriate model for the E-selectin binding
data generated with the centrifugation assay (Piper et al.,
1998). It will be demonstrated later that Eq. 3 also describes
the CD16/IgG binding data well.
Relation to existing models
Reduction of Eq. 2b to its deterministic counterpart can be
done by multiplying both sides of Eq. 2b by m (or n) and
summing over both m and n to obtain two equations for the
average numbers of 3D (	m
) and 2D (	n
) bonds:
d	m

dt  kf,3DcAcmr 	m
 	n
 kr,3D	m
 (4a)
d	n

dt  	kf,2D
(n1)
mlAcmr 	m
 	n
 	kr,2D(n) 
	n

 ml	kf,2D(n1) m
 	kf,2D(n1)
	m
 ml	kf,2D(n1) n

 	kf,2D(n1)
	n
 	kr,2D(n) n
 	kr,2D(n) 
	n
 (4b)
where 	 
 denotes averaging. Relating the average numbers
of bonds to their densities, Eq. 4 can be recognized as the
deterministic kinetic equations for reaction Eq. 1b. When
both sides are divided by a volume to convert numbers of
molecules to their concentrations, Eq. 4a becomes identical
to Eq. 2a. The three terms in the parentheses on the second
line of Eq. 4b are cross-correlation functions resulting from
the dependence of the 2D kinetic rates on n. They are
measures of fluctuations and as such their contributions to
Eq. 4b diminish as the system becomes large and statisti-
cally stable. The steady-state and large system limit of Eq.
4 (obtainable by setting the left-hand side to zero and
neglecting the cross-correlation terms) is equivalent to the
equations from which the 3D/3D competition binding the-
ory is derived (Cheng and Prusoff, 1973).
Needless to say, it is the 2D not 3D bonds that mediate
the physical linkage of cell adhesion. The marginal proba-
bility distribution of the 2D bonds is defined by pn mpnm.
Summing Eq. 2b over m, one obtains
dpn
dt  kf,2D
(n) mlAcmr n 1pn1 kr,2D(n1)n 1pn1
 kf,2D(n1) mlAcmr n kr,2D(n) npn
 ml 
m
mkf,2D(n1) pnm kf,2D(n) pn1m  (5)
This is the binomial type of the masters equations discussed
by Piper et al. (1998), except for the addition of the last
summation term on the right-hand side.
Approximate solutions
In the absence of active spreading, the number of 2D bonds
is typically very small, as their formation is limited by the
cell surface roughness (Piper et al., 1998; Chesla et al.,
1998; Williams, 1998). In contrast, soluble competitors can
access all unoccupied cell surface receptors, even if they are
hidden in the membrane folds (Williams, 1998). As such,
the number of 3D bonds is much larger, even at low com-
petitor concentrations. This allows us to neglect the fluctu-
ations in the 3D bonds and to approximate the summation
terms in Eq. 5 by

m
mpnm  	m
pn  pnAcmr/1 Kd,3D/c (6)
The first approximate expression in Eq. 6 would not be
exact unless the two ligands were independent (C. Zhu and
T. E. Williams, manuscript submitted for publication),
which is not the case here because the surface and soluble
ligands are in competition for the same receptor. The second
approximate expression in Eq. 6 follows from Eq. 4a (the
3396 Biophysical Journal Volume 77 December 1999
steady-state version) when 	m
  	n
, which is clearly the
case here. Substituting Eq. 6 into Eq. 5 recovers the bino-
mial type of the masters equations discussed by Piper et al.
(1998), except that the receptor number in the contact area,
Acmr, is now scaled by a factor (1 cKa,3D). Its steady-state
solution applicable to the centrifugation experiment is (Pip-
er et al., 1998)
pn p0Acmr/1 cKa,3Dn 
i1
n
mlKa,2Dfi n 0
(7a)
where
p0 1 
n1
Acmr/(1cKa,3D) Acmr/1 cKa,3Dn 
i1
n
mlKa,2Dfi1
(7b)
The probability of adhesion is that of having at least one
bond, i.e., Pa  1  p0.
The validity of the above approximate solutions is tested
in Fig. 1, where the ratio of Pa given by Eq. 7b to that of the
exact solution to the full master equations (Eq. 2b) is plotted
against Acmr/(1  cKa,3D) for various cKa,3D (Fig. 1 A) and
mlKa,2D0 (Fig. 1 B). These parameters represent the respec-
tive propensities of forming 3D and 2D bonds. It is evident
that when Acmr/(1  cKa,3D) approaches 1, the approxima-
tion breaks down, as revealed by the significant deviation of
the Pa ratio from unity. However, as Acmr/(1  cKa,3D)
increases beyond 10, i.e., the average number of 3D bonds
is large relative to cKa,3D, the Pa ratio quickly approaches
unity, indicating that Eq. 7 is a good approximation to the
exact solution to Eq. 2b in these parameter regimes, which
correspond to the conditions of our experiment.
Following Piper et al. (1998), an approximate solution
can be derived for the case of rare adhesion, Pa  1:
Pa  AcmrmlKa,2Df/1 cKa,3D (8)
Setting c  0 reduces Eqs. 7 and 8 to the corresponding
equations discussed by Piper et al. (1998), as required.
Relating IC50 to affinity
By definition, ICx is the concentration of the soluble com-
petitor required to achieve x% of inhibition. For the case of
nearly complete inhibition, Eq. 8 is applicable:
ICx  AcmrmlKa,2Df1 x%Pa,0  1Kd,3D (9)
where Pa,0 is the adherent fraction in the absence of a
soluble competitor. This is similar to the Cheng and Prusoff
formula for measuring the dissociation constant, Kd,3D, of a
competitor for its receptor, using a ligand of known affinity.
The Cheng and Prusoff equation was derived for 3D/3D
competition, whereas Eq. 9 applies to 2D/3D competition.
Because ICx is proportional to Kd,3D, the higher the com-
petitor’s affinity, the lower the concentration required to
achieve the same level of inhibition. Thus Eq. 9 offers a
design tool for receptor-based competitive inhibition ther-
apy, which may be used to guide the dosage of inhibitor
administration.
Pa,0  AcmrmlKa,2D(f) when Pa,0 itself is small compared
to unity, which results in further simplification of Eq. 9:
Kd,3D 
1 x%
x% ICx (10a)
In particular, when x  50,
Kd,3D  IC50 (10b)
FIGURE 1 Comparison between exact and approximate solutions to the
master equations. The Pa ( 1  p0) ratio of the approximate analytical
solution, Eq. 7b, to the numerical solution to the full master equations, Eq.
2b, is plotted against the available receptor number in contact area Acmr/
(1  cKa,3D) (	m
/cKa,3D) for various cKa,3D (A) and mlKa,2D0 (B) values
as indicated. Note that the experimental conditions in the present work
satisfy Acmr/(1  cKa,3D)  10, which is within the parameter range that
validates the approximation.
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Thus, when adhesion is infrequent, the 3D equilibrium
dissociation constant can be approximated by the IC50.
These results are interesting and may be useful in designing
simple experiment to estimate the Kd,3D (see Results).
MATERIALS AND METHODS
Cells and antibodies
Our CD16a-expressing Chinese hamster ovary (CHO) cell transfectants
have previously been described (S. E. Chesla, P. Li, S. Nagarajan, P.
Selvaraj, and C. Zhu, manuscripts submitted for publication). The anti-
CD16 mAb CLBFcgran-1 (murine IgG2a) and irrelevant control mAb X63
(murine IgG1) were purified in house from hybridomas as previously
described (Selvaraj et al., 1988). The cleaving of CLBFcgran-1 into Fab
fragment was done by Lampire (Pipersville, PA). The fluorescein isothio-
cyanate (FITC)-conjugated goat anti-mouse polyclonal antibody used in
flow cytometry was purchased from Sigma Chemical Company (St. Louis,
MO). Two types of rabbit (Rb) IgG were also purchased from Sigma. One
was a specific polyclonal antibody against bovine serum albumin (BSA)
(in IgG fraction), which was used as a surface-bound ligand. The other was
nonspecific RbIgG that did not react with BSA and would not be absorbed
onto a BSA-coated plastic surface. This was used as a soluble competitor.
Receptor density determination
Quantitative indirect fluorescent immunoassay (QIFI) (Serke et al., 1998;
Bikoue et al., 1996) was used to quantify the expression of CD16a on CHO
cell transfectants, as previously described (Chesla et al., 1998). We found
that receptor site density measured by QIFI correlated well with radioim-
munoassay (RIA) using 125I-labeled proteins (Chesla et al., 1998). Briefly,
CD16a-expressing CHO cells stained with primary mAbs CLBFcgran-1
(anti-CD16) or X63 (negative control) and FITC-conjugated anti-mouse
secondary antibody were analyzed by flow cytometry. A calibration curve
between the mean fluorescence intensity and the number of FITC mole-
cules was generated using standard beads. The number of CD16a on the
CHO cell surface was calculated based on the number of FITC molecules
per cell and per anti-mouse goat antibody (provided by the manufacturer).
Labeling anti-BSA RbIgG with FITC
Anti-BSA RbIgG was dialyzed with FITC labeling buffer for 2 days with
three buffer changes. Ten microliters of 10 mg/ml FITC (Sigma) in
dimethyl sulfoxide was added to 1 ml of 1 mg/ml RbIgG. The mixture was
incubated for 2 h at room temperature. The FITC-labeled RbIgG was
dialyzed with phosphate-buffered saline (PBS) for 2 days with three buffer
changes.
Coating of RbIgG and determination of their
surface density
Previously, we quantified the surface density of coated molecules by RIA
(Piper et al., 1998). In the present work the site density of immobilized
anti-BSA RbIgG was determined fluoremetrically. Ninety-six-well micro-
titer plates (Corning, Cambridge, MA) were coated with 1% IgG-free BSA
(Sigma) in PBS/EDTA at 4°C overnight. After two washes with PBS/
EDTA, variable concentrations of unlabeled (for centrifugation experi-
ment) or FITC-labeled (for site density determination) anti-BSA RbIgG in
PBS were added to the wells (50 	l per well) and incubated for 30 min at
4°C. In some control centrifugation experiments nonspecific RbIgG not
reactive to BSA was used instead of anti-BSA RbIgG. The wells were
washed with PBS/EDTA twice before being used in the centrifugation
experiment or being read in a fluorescence plate reader (Biorad, Hercules,
CA) for site density determination. As shown in Fig. 2 A, the measured
fluorescence intensity appears to be a linear function of the mass of
FITC-labeled RbIgG in the range tested. Using this as calibration, we
determined the relationship between the site density of RbIgG immobilized
on 96-well plates and the RbIgG solution concentration used to coat the
surface, as showed in Fig. 2 B. The linear relationship seen in Fig. 2 B
indicates that the concentration of anti-BSA RbIgG used was well below
that required to saturate the BSA sites on the wells coated with 1% BSA.
Gel filtration
Aggregated IgG is a multivalent ligand and binds to CD16 with high
avidity. Therefore, the presence of even a small fraction of aggregated IgG
FIGURE 2 Determination of RbIgG coating density. (A) FITC-conju-
gated anti-BSA RbIgG of a known amount (0, 15.6, 31.2, 62.5, 125, and
250 ng) was added to wells of a 96-well plate. The wells were read with a
fluorescence plate reader. The fluorescence intensity of the wells without
FITC-RbIgG was used as the background and subtracted from the reading
of wells with FITC-RbIgG. Data (points) were presented as mean 
standard deviation of quadruplicate wells. A straight line was fit to the data.
(B) FITC-labeled anti-BSA RbIgG of known concentrations (0, 3.1, 6.2,
12.5, 25, and 50 	g/ml) was immobilized on BSA-coated wells of a
96-well plate as described in the text. After the background was subtracted
(fluorescence reading of the wells without FITC-RbIgG), the fluorescence
reading was converted to site density, using the relationship established in
A. The line is a linear fit to the data (points, mean  standard deviation of
quadruplicate wells).
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may lead to erroneous result in assays intended for monomeric IgG. In
order to remove large-sized aggregated IgG, before each centrifugation
experiment 150 mg of RbIgG in 5 ml PBS/EDTA was spun in a micro-
centrifuge at high speed at 4°C. The monomeric RbIgG was further
separated from oligomers by size exclusion chromatography. Briefly,
RbIgG in 5 ml PBS/EDTA was passed through a Sephadex G-200 (Phar-
macia, Piscataway, NJ) column (500 ml in bed volume, 2.5 cm in diame-
ter). The flow rate was set to be 0.25 ml/min. The flow through was
collected by a fraction collector (Biorad) with 5 ml in each fraction. The
optical density of each fraction was measured in a spectrometer at 280 nm.
Fractions of monomeric or aggregated IgG were concentrated in protein
concentrators (Millipore, Bedford, MA), the concentrations of which were
determined with a protein estimation kit (Biorad). When the concentrated
monomeric RbIgG was passed through the gel filtration column again only
a single peak was seen, indicating that the concentration procedure did not
produce reaggregation. The centrifugation experiments were always done
immediately after the gel filtration and concentration.
Fluorescent labeling of CHO cells
CHO cells were detached by and washed twice with PBS/EDTA. They
were resuspended in PBS at 5  106 cells/ml. Ten mg/ml of calcein AM
(Molecular Probes, Eugene, OR) was added to the cell suspension in the
ratio of 1 	l to 1 ml. The cells were incubated at room temperature for 30
min. The labeled cells were washed twice with binding buffer (0.4% OVA
(Sigma) in PBS/EDTA). For each batch of labeled cells, a calibration curve
was generated to relate the fluorescence intensity and the number of cells
present. As can be seen in Fig. 3, the fluorescent intensity of the wells
appears as a linear function of the number of labeled CHO cells, providing
a simple conversion between the two. The present fluoremetric method has
several advantages over our previous radiometric technique using 51Cr-
labeling (Piper et al., 1998). The 96-well plate can be read directly by a
fluorescence plate reader without transferring the individual wells to the 
counter.
Centrifugation experiment
One hundred fifty microliters of fluorescently labeled CD16a-expressing
CHO cells at a concentration of 2  105 cells/ml in binding buffer with
varying concentrations of soluble competitor (RbIgG or Fab fragment of
CLBFcgran-1) was added to each anti-BSA RbIgG-coated well and incu-
bated for 45 min at 4°C. The wells were filled up with corresponding
concentrations of competitor in binding buffer, incubated for another 45
min at 4°C, then sealed with plate sealers and spun in a centrifuge at a
desired speed for 3 min. The plates were inverted in cold PBS/EDTA to
remove detached cells and read by a fluorescent plate reader. The fraction
of adherent cells was calculated in a fashion similar to that of the calcu-
lation of the ligand site density, using standards to remove nonspecific
contribution and to convert fluorescence intensity into cell numbers.
Size and density measurements of CHO cells
The centrifugal force (f, in pN) was calculated from the spinning speed (
,
in rad/s), the distance from the cell and the axis of rotation (l, in m), and
the volume (V, in 	m3) and density (c, in g/cm3) of the CHO cells
according to f  
2l(c  m), where m is the medium density. Cell size
was directly measured microscopically, which followed a broad log normal
distribution as previously noted for other cells (Piper et al., 1998). The
mean and standard deviation of the cell volume were 1351 and 617 	m3,
respectively. The density of the CHO cells was measured by centrifugation
through a continuous density gradient with calibration beads of known
densities (Zhu et al., 1999). The result was c  1.050 g/cm
3.
Numerical solution of master equations
Equations 2b and 3 were solved at steady state, using an iterative algo-
rithm. Briefly, upon assuming an initial set of pnm(ti) the pnm values at the
next time point ti1 were calculated from (pnm(ti1)  pnm(ti))/(ti1  ti) 
RHS(ti), where RHS is the right-hand side of Eq. 2b. The iteration con-
tinued with increasing i values until maxn	pnm(ti1)  pnm(ti)	  , where 
is the assigned convergence criterion (105). pnm(ti1) was the solution at
equilibrium.
RESULTS
Confirmation of binding specificity
Fig. 4 shows that CD16a-expressing CHO cells bound well
to wells incubated consecutively with IgG-free BSA and
rabbit anti-BSA antibody. In contrast, the same CHO cells
did not bind to BSA-treated wells with or without the
second-step incubation with irrelevant RbIgG, indicating
the requirement of surface-bound ligand. Similarly, untrans-
fected CHO cells or CHO cells transfected to express an
irrelevant receptor, B7, did not bind to wells incubated
consecutively with BSA and anti-BSA RbIgG, indicating
the requirement for the cell surface receptor. Therefore, it
was confirmed that the adhesion assayed here was indeed
mediated by the specific binding of cell surface CD16a to
anti-BSA RbIgG coated on the wells. The binding specific-
ity was further demonstrated in the competition experiment,
where adhesion was inhibited progressively by soluble
RbIgG and Fab fragment of CLBFcgran-1 (Figs. 6 and 9).
Testing the steady-state assumption
The temporal resolution of the centrifugation assay is on the
order of a minute, which is longer than the transient time
scale (seconds) of the CD16a-IgG-mediated cell adhesion as
characterized by the reciprocal kinetic rate constants,
FIGURE 3 Fluoremetric determination of adherent cells. CD16a-ex-
pressing CHO cells were labeled with calcein AM. Suspensions containing
a known number of cells (0, 938, 1,875, 3,750, 7,500, 15,000, and 30,000)
were added to the wells of a 96-well plate via serial dilution. The plate was
read with a fluorescence plate reader. The fluorescence reading of the wells
without cells was used as the background and subtracted from the reading
of wells with cells. Data (points) were presented as mean  standard
deviation of quadruplicate wells. A straight line was fit to the data.
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1/(mrmlAckf) and 1/kr (Chesla et al., 1998; Chesla et al.,
manuscript submitted for publication). For this reason, the
steady-state solution of our model, Eq. 7, was used to
analyze the centrifugation data. To ensure the achievement
of a steady state in our experiments, the cells were incubated
with the ligand-coated surface for a total of 90 min during
the attachment phase. During the detachment phase the
steady-state assumption was tested by spinning the cells
over varying periods of time. The lack of dependence of the
adherent fraction on the duration of force application up to
16 min is clearly evident from Fig. 5. These data suggest
that the steady state had been reached before the shortest
time point (2 min) tested, as prolonged spinning at the same
speed did not detach any more cells.
Inhibition of CD16a-expressing CHO cell
adhesion to RbIgG-coated surface by
similar competitor
In one set of centrifugation experiments, soluble RbIgG was
allowed to compete with surface-bound RbIgG for binding
of cell surface CD16a. This was designed to address the
question of whether the serum IgG would prevent binding
of leukocyte FcRs to IgG immobilized on surfaces of
target cells or blood vessel walls. These data should also be
relevant to receptor-based competitive inhibition therapy, in
which a competitor similar to the surface-bound molecule is
used.
To minimize interexperimental variations, we used the
same batch of cells in side-by-side experiments and simul-
taneously measured their adhesions to wells coated with
four different anti-BSA RbIgG densities, in the presence of
six different soluble RbIgG (nonreactive to BSA) concen-
trations, and under four different centrifugal forces. Repre-
sentative data are exemplified in Fig. 6. It is evident that, for
a given ligand coating density and centrifugal force, the
adhesion fraction decreased with the increasing soluble
competitor concentration. Also, the adhesion fraction in-
creased with increasing surface ligand coating density for
fixed competitor concentration and centrifugal force. Fi-
nally, for any competitor concentration and ligand coating
density, the adhesion fraction decreased with the increasing
centrifugal force. These qualitative trends appear reason-
able, as they follow an expected pattern.
Comparison of theory to experiment
To test the validity of the model, the solution to Eqs. 2b and
3 (curves) was fit to the experimental data (points) in Fig. 6.
It should be emphasized that we fitted the prediction to the
entire set of data of a total of 16 curves with six points for
each curve, not just an individual curve. As can be seen
from Fig. 6, the agreement between the theory and experi-
ment is surprisingly good, considering the complexity of the
data (multivariables, wide ranges, and large number of
points) and the limited number of free fitting parameters.
The agreement between theory and experiment thus sup-
ports the validity of our model. The three fitting parameters
are the 3D and 2D affinities, Ka,3D and AcKa,2D0 , and the
bond parameter, a. The best-fit values of these are listed in
Table 1.
Dependence of IC50 on ligand density and
centrifugal force
Each inhibition curve in Fig. 6 has its own IC50, the con-
centration of the soluble competitor required to achieve
FIGURE 4 Demonstration of binding specificity. The wells of a 96-well
plate coated with IgG-free BSA were incubated with 25 	g/ml of anti-BSA
RbIgG or irrelevant RbIgG that did not react with BSA or plain PBS (—).
The adhesion to these wells of fluorescently labeled untransfected CHO
cells (plain) or CHO cells transfected to express CD16a or B7 was assayed
in a centrifugation experiment (300 rpm) as described in the text. It is
evident that significant binding occurred only between CD16a-expressing
CHO cells and BSA-coated wells treated with anti-BSA RbIgG.
FIGURE 5 Lack of effect of spinning duration on cell detachment.
Binding of CD16a-expressing CHO cells to wells coated with 450 sites/
	m2 anti-BSA RbIgG in the presence of 53 	g/ml of soluble RbIgG
(nonreactive to BSA) was assayed by centrifugation at 300 rpm for differ-
ent spinning times (2, 4, 8, and 16 min). Data are presented as mean 
standard deviation of quadruplicate wells.
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50% of inhibition. While this phenomenological index is
commonly used to measure the efficacy of a soluble com-
petitor, it should be emphasized that IC50 depends on ml, the
RbIgG coating density, and f, the applied centrifugal force.
This dependence was measured from the experimental data
in Fig. 6 and compared to the model predictions, as shown
in Fig. 7. As expected, the higher the adhesion (as a result
of higher ligand density and/or lower the centrifugal force),
the higher the competitor concentration required to achieve
the same level of inhibition, and thereby the higher the IC50.
Only when the adhesion fractions become small do all IC50
curves approach a constant. Our model predicts that this
constant is Kd,3D, the equilibrium dissociation constant of
the soluble competitor for the cell surface receptor. It is
evident from Fig. 7 that this prediction is supported by the
data. Thus Kd,3D can be estimated from IC50, using a simple
adhesion assay, provided that the initial binding in the
absence of the competitor is sufficiently low.
Direct measurement of AcKa,2D(f)
The reduced adhesion when a higher centrifugal speed was
applied (Fig. 6) suggests a decrease in the 2D affinity with
FIGURE 6 Centrifugation experiment with similar
competitor. Binding of CHO cells expressing 860
sites/	m2 of CD16a to variable densities (indicated)
of surface-bound anti-BSA RbIgG in the presence of
different concentrations (0, 53, 105, 210, 420, and 840
	g/ml) of soluble RbIgG (nonreactive to BSA) was
assayed by centrifugation at 300 (A), 450 (B), 630 (C),
and 760 (D) rpm. Data (points) are presented as
mean  standard deviation of quadruplicate wells.
The curves are a single least 2 fit to all of the data
based on Eqs. 2b and 3. The experiment was repeated
three times, and the results shown are representative.
TABLE 1 Summary data (best-fit value  standard deviation)
for CD16a binding affinity
Soluble
competitor Ka,3D (M1) AcKa,2D0 (	m4) a (nm)
RbIgG (2.0  0.085)  106 (8.0  0.19)  106 0.1  0.02
CLBFcgran-1 (9.1  0.22)  108 (7.5  0.18)  106 0.1*
Three-dimensional affinities are for soluble competitors (RbIgG and Fab
fragment of CLBFcgran-1). Two-dimensional affinities are for surface-
bound RbIgG but measured from experiments using difference soluble
competitors.
* Not a fitting parameter but fixed as model input.
FIGURE 7 Dependence of IC50 on ligand density and centrifugal force.
IC50 corresponding to different ml was measured from the data in Fig. 6 and
plotted against f (points). The curves were theoretical predictions based on
Eqs. 2b and 3 and parameter values AcKa,2D0  8.0  106 	m4 and a 
0.1 nm. These curves asymptotically approach a horizontal line that inter-
cepts the y axis at 0.5 	M, which is equal to Kd,3D (cf. Table 1).
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increasing dislodging force, as modeled by Eq. 3. In addi-
tion to fitting Eqs. 2b and 3 to all data in Fig. 6 to evaluate
the model parameters and then using Eq. 3 to predict
AcKa,2D(f), the dependence of the 2D affinity on force can
also be directly measured from the low adhesion data points
(Pa  0.2) in Fig. 6. For each centrifugal force and ligand
density, Pa(1  cKa,3D)/mlmr values were calculated and
averaged over all competitor concentrations to give rise to
an estimate for AcKa,2D (see Eq. 8). This was plotted against
force in Fig. 8 for each ligand density. The lack of depen-
dence of the AcKa,2D versus f curve on ml supports the
validity of Eq. 8. Using Eq. 3 and parameters listed in Table
1, the force dependence of the 2D affinity was plotted in
Fig. 8. It is evident that the theoretical curve compares quite
well with the directly measured AcKa,2D(f) data, providing
further support for our model.
Inhibition of CD16a-expressing CHO cell
adhesion to a RbIgG-coated surface by
dissimilar competitor
In another set of centrifugation experiments, the soluble
competitor was changed to CLBFcgran-1, which was dif-
ferent from the surface-bound ligand. This was designed to
determine the concentration at which a mAb directed
against CD16 would be effective in blocking unwanted
adhesion mediated by the CD16/IgG interaction. These data
should also be relevant to receptor-based competitive inhi-
bition therapy, in which antibodies or receptor or ligand
analogs are used as competitors.
The fractions of CD16a-expressing CHO cells adherent
to wells coated with four different anti-BSA RbIgG densi-
ties were measured in the presence of six different soluble
CLBFcgran-1 concentrations. Fab fragment was used in-
stead of the whole antibody to ensure 1:1 stoichiometry and
to avoid the potential interaction of the Fc portion of the
murine IgG with CD16a. Typical results are shown in Fig.
9. The pattern of inhibition of CHO cell adhesion by CLBF-
cgran-1 is similar to that by soluble RbIgG, except that a
much lower concentration of CLBFcgran-1 is needed for the
same level of inhibition. This is expected, as CLBFcgran-1
has a much higher affinity for CD16a than RbIgG. The
curves are the least 2 fitting of the solution to Eqs. 2b and
3 to the experimental data. Because centrifugal force was
not varied in this experiment, it was not possible to deter-
mine the bond parameter from the data. Instead, the same a
value (0.1 nm) as estimated from the data in Fig. 6 was
used as an input to the model, leaving Ka,3D and AcKa,2D0 as
the only freely adjustable fitting parameters. This seemed
reasonable, as the cell adhesion in both cases was mediated
by the same CD16a/RbIgG interaction despite the fact that
different soluble competitors were used. Again, good agree-
ment was found between the model prediction and the
experiment data. The best-fit values of the 3D affinity of
CLBFcgran-1 Fab to CD16a and the 2D affinity of CD16a
for RbIgG are listed in Table 1.
DISCUSSION
Validity of the model
The 2D/3D competition experiment is widely used for as-
saying the potency of a soluble inhibitor. While the data
shown in Figs. 6 and 9 are commonly seen, the present work
contributes a mathematical model that predicts the expected
qualitative dependency of adhesion on physiochemical vari-
FIGURE 8 Relationship between 2D binding affinity and force on a cell.
The average ratio of binding fraction, Pa (with values not exceeding 0.2),
to the product of ligand density, ml, and effective receptor density, mr/(1 
cKa,3D), for the points of the constant ml curves (values indicated) shown
in Fig. 6 is plotted against the force on a cell (calculated from the
centrifugal speed). This provides a direct measure of AcKa,2D(f), as it can
be approximated by Pa(1  cKa,3D)/mrml when Pa is small (cf. Eq. 8). The
curve is a theoretical prediction based on Eq. 3 and parameter values
AcKa,2D0  8.0  106 	m4 and a  0.1 nm.
FIGURE 9 Centrifugation experiment with dissimilar competitor. Bind-
ing of CHO cells expressing 360 sites/	m2 of CD16a to variable densities
(indicated) of surface-bound anti-BSA RbIgG in the presence of different
concentrations (0, 0.15, 0.3, 0.6, 1.2, and 2.4 ng/ml) of Fab fragment of
anti-CD16 mAb CLBFcgran-1 was assayed by centrifugation (300 rpm).
Data (points) are presented as mean  standard deviation of quadruplicate
wells. The curves are a single least 2 fit to all of the data based on Eqs.
2a and 3, with the best-fit parameter values shown in Table 1. The experiment
was repeated three times, and the results shown are representative.
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ables in a highly quantitative fashion. Moreover, comparing
the theory with experiment allows us to evaluate intrinsic
binding properties, such as AcKa,2D0 and Ka,3D. The validity
of the model has been supported by its abilities to account
for the data and to predict accurately the binding properties.
To test the model rigorously, we quantified the depen-
dence of adhesion on multiple variables over a wide range.
For the similar competitor experiment (Fig. 6), the test was
quite challenging: it required that the model simultaneously
fit 96 data points in 16 experimental curves due to changes
in three variables (c, ml, and f). The ability of the model to
account for all data using only three parameters (Ka,3D,
AcKa,2D0 , and a) thus provided substantial support for its
validity.
The fitting of the theory to the dissimilar competitor
experiment (Fig. 9) was also very successful, providing
further support to the model. While the competitor was
changed to a mAb (CLBFcgran-1) with an affinity two to
three orders of magnitude higher, it was the same 2D
interaction, the binding of CD16a-expressing CHO cells to
RbIgG-coated wells, that was inhibited. As such, the same
2D binding parameter should be obtained. The value of
AcKa,2D0 (8.0 106 	m4) estimated from fitting the data in
Fig. 6 is indeed in excellent agreement with the value (7.5
106 	m4) calculated from the data in Fig. 9.
The same parameter has also been measured recently by
a newly developed micropipette method (S. E. Chesla, P. Li,
S. Nagarajan, P. Selvaraj, and C. Zhu, manuscripts submit-
ted for publication). These workers used the same CD16a-
expressing CHO cells, but the RbIgG was coated on the
surface of human red blood cells. The contact area there was
probably somewhat different from the Ac in the centrifuga-
tion experiment. Despite the differences in the methods and,
probably, in the Ac values, the AcKa,2D0 (2.8  106 	m4)
value reported by these authors is remarkably similar to
those obtained herein. Thus the 2D affinity value is inde-
pendent of the soluble competitors and experimental tech-
niques used for its measurement. This indicates that it
represents an intrinsic binding property of the interaction in
question rather than merely a curve-fitting parameter.
Another binding property, also evaluated from comparing
the predicted with the measured 2D/3D competition curves,
is Ka,3D of the cell surface CD16a for the soluble compet-
itor. We calculated a Ka,3D of 2.0 106 M1 for RbIgG and
9.1  108 M1 for CLBFcgarn-1 Fab, respectively, from
the data shown in Figs. 6 and 9. These affinities were also
measured using, respectively, 3D/3D competition and Scat-
chard analysis (S. E. Chesla, P. Li, S. Nagarajan, P. Sel-
varaj, and C. Zhu, manuscript submitted for publication).
The values reported by these authors are 0.93  106 M1
and 1.0  108 M1 for RbIgG and CLBFcgarn-1 Fab,
respectively. The Ka,3D for the CD16a/RbIgG interaction is
reasonably consistent with the value obtained herein. We
suspect that the low Ka,3D for CD16a/CLBFcgarn-1 inter-
action from our previous work might be due to iodination of
CLBFcgarn-1, which might have adversely affected its
binding capacity. In fact, our most recent measurement
using the surface plasmon resonance technique yielded a
value of 4.2  108 M1 for CLBFcgarn-1 Fab binding to
soluble CD16a (Li, 1999), which is in fair agreement with
the value obtained herein.
Application to P-selectin system
Applying our model, we analyzed a 2D/3D competition
binding experiment reported by Ushiyama et al. (1993).
These authors coated the membrane form of P-selectin on
wells of 96-well plates. The adhesion of P-selectin glyco-
protein ligand 1 (PSGL-1)-expressing HL-60 cells to the
coated wells was assayed by a plate inversion experiment
(1-g sedimentation) in the presence of two forms of soluble
monomeric P-selectin at varying concentrations. They also
conducted an independent experiment of cell adhesion in
the absence of soluble competitors. This allowed Piper et al.
(1998) to evaluate the 2D affinity of membrane P-selectin
for PSGL-1. Using this AcKa,2D0 (1.3  103 	m4) as input,
we fitted the solution of Eqs. 2b and 3 to the competition
data of Ushiyama et al. (1993). It is evident from Fig. 10
that the theory compares quite well with the experiment.
The only curve-fitting parameter is the affinity of the solu-
ble P-selectin. The best-fit Ka,3D are 2.0 106 M and 1.8
106 M1, respectively, for the truncated and alternatively
spliced forms of P-selectin. These values are in good agree-
ment with the soluble P-selectin/PSGL-1 affinity ( 3.3 
106 M1) recently measured with the surface plasmon res-
onance method (Mehta et al., 1998).
FIGURE 10 Comparison of model prediction with P-selectin data from
Ushiyama et al. (1993). Adhesion of HL-60 cells (expressing 63 sites/	m2
PSGL-1 sites for P-selectin binding) to wells of a 96-well plate coated with
10 sites/	m2 membrane P-selectin in the presence of various concentra-
tions of either the alternatively spliced (as-) or truncated (t-) soluble form
of P-selectin was measured in a plate inversion (1-g sedimentation) assay.
The curves are least 2 fits to the data (from Ushiyama et al., 1993, by
permission), based on Eqs. 2b and 3 with predetermined parameters
AcKa,2D0  1.3  103 	m4 (Piper et al., 1998) and a  0.04 nm (Alon et
al., 1997). The only freely adjustable parameter is Ka,3D, the best-fit values
of which are 1.8 and 2.0  106 M1 for as- and t-P-selectin, respectively.
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Relationship between IC50 and Kd,3D
Binding affinity reflects the propensity of the ligand to bind
the receptor. IC50 is a measure for the potency of the soluble
molecule to competitively inhibit 2D binding. The correla-
tion between IC50 and Kd,3D has been noted for quite some
time (Casasnovas and Springer, 1995). The present work
has derived a theoretical relationship between the two (e.g.,
Eq. 9), which has been tested by experiment (Fig. 7). The
qualitative trends shown in Fig. 7 also make good sense
intuitively. Kd,3D can be interpreted as the concentration
required for a binding curve to achieve half-saturation. For
a low level of initial adhesion, due to high dislodging force
or to low density of the receptor or ligand, many of the
adherent cells must be mediated by just a single bond (Piper
et al., 1998; Chesla et al., 1998). A concentration of the
soluble competitor that would block half of the receptors
would reduce half of the bonds, thereby reducing the num-
ber of adherent cells by a half. Thus IC50  Kd,3D when
Pa  1. If the initial level of adhesion is high, on the other
hand, binding is more likely to be mediated by multiple
bonds. Reducing the number of bonds by a half will weaken
many adherent contacts, but less than half of them would
dissociate. In other words, to reduce adhesion by a half
requires a higher competitor concentration. Thus IC50 
Kd,3D when Pa  1.
Is the constant contact area assumption valid?
The contact area Ac between the adherent cell and the
ligand-coated surface has been assumed constant in our
model. This assumption seems reasonable during attach-
ment because of the low number of bonds. Intuitively, Ac
will not depend on the number of bonds if there exist only
a few of them per cell, because bonds are only formed in a
small fraction of the total contact area. In other words, when
there is still a large fraction of the contact area without any
bonds due to the low affinity of the CD16/IgG interaction,
Ac will not increase with the increasing number of bonds
until the bonds have populated all available contact area.
The evidence supporting the constant contact area as-
sumption during detachment is as follows. Should Ac in-
crease with the number of 2D bonds, then the parameter
AcKa,2D0 evaluated from curve-fitting of the centrifugation
data would have been an increasing function of the binding
fraction Pa instead of a constant, because the higher the Pa,
the more 2D bonds there are, and the larger is Ac. This was
not observed, however. To the contrary, the AcKa,2D0 value
calculated from fitting the entire data set of the similar
competitor experiment that includes many high binding
fraction data points (Fig. 6) agrees quite well with that
computed using only a subset of the data that correspond to
Pa  0.2 (Fig. 8) and with that derived from fitting the
dissimilar competitor experiment, the binding fractions of
which are much lower (Fig. 9).
However, the constant contact area assumption seems
counterintuitive, as we could think of an argument against
it. For a cell initially bound by a few bonds, dissociation of
some of them would result in readjusting the cell’s position
by the applied force, leading to a reduction in Ac. This issue
is related to an unresolved puzzle of the centrifugation
method, namely, the steady-state paradox (Piper et al.,
1998).
Unresolved steady-state paradox
The reverse rates of the CD16/IgG interactions have been
measured to be fractions of a reciprocal second (Chesla et
al., 1998; S. E. Chesla, P. Li, S. Nagarajan, P. Selvaraj, and
C. Zhu, manuscripts submitted for publication). Our model
assumes that the adhesion is mediated by a low number of
bonds. The question is, how could a cell bound by a few
bonds of short lifetime sustain a steadily applied force?
Should the contact area be reduced by the dissociation of
some of the bonds, this would reduce the opportunity for
rebinding, which would move the system away from the
steady state toward detachment.
The achievement of steady state during the attachment
phase was ensured by a long incubation time (90 min total).
During the detachment phase this was verified by the lack of
dependence of adhesion on the duration of force application
up to 16 min (Fig. 5).
The low bond number assumption was examined very
carefully. Perhaps the most compelling evidence supporting
this assumption is the weakness of adhesion seen in our
experiment. When the adherent fraction is small, one mea-
sure of the physical strength of cell adhesion, defined as the
force required to detach 50% of the cells adherent in the
absence of force, can be expressed as
f50 
kBT
a ln 2 (11)
using Eqs. 3 and 8. For a  0.1 nm (Table 1), f50  28 pN
at room temperature. This is smaller than twice the value of
the single bond strength (18 pN), determined from analyz-
ing the histogram of over a 1000 single-cell detachment
forces measured by micropipette experiment, using CD16a-
expressing CHO cells and IgG-coated red cells (Zhu and
Chesla, 1997). In addition, all lines of reasoning presented
in our earlier publication (Piper et al., 1998) in support of
the small bond number assumption also apply here.
Thus, both steady-state and small bond number assump-
tions seem to be supported experimentally, and we are
facing the same paradox as Piper et al. (1998). In fact, one
of the objectives of the present work was to reexamine this
paradox by using another biological system and by extend-
ing our previous model to include soluble competitors.
Unfortunately, to date we have not found an answer to this
puzzle, and additional work is required to resolve the
steady-state paradox.
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Analysis of physiological cases
Applying the model developed herein, let us evaluate quan-
titatively some in vivo situations to see whether the pres-
ence of soluble receptors or ligands can inhibit 2D binding.
Soluble human (h) IgG as high as 8–12 mg/ml (50–80 	M)
exists in human blood (Allansmith et al., 1968). How would
such a high concentration of soluble competitors influence
the ability of leukocyte FcRs to adhere to antibody-coated
surfaces? Using an AcKa,2D0 value of 7.4  107 	m4 for
CD16a/hIgG interaction (Chesla et al., 1998) and assuming
mr and ml to be 100 and 1000 sites/	m2 respectively, Eq. 8
predicts an adhesion probability of 7.4% in the absence of a
soluble competitor without force. Taking a Ka,3D value of
2.5  105 M1 for the same CD16a/hIgG interaction (S. E.
Chesla, P. Li, S. Nagarajan, P. Selvaraj, and C. Zhu, manu-
script submitted for publication), Eq. 10a predicts 95%
inhibition by the presence of 80 	M serum IgG. Similar
predictions can be made for other FcRs if they also have a
similar Ka,3D/Ka,2D0 ratio. This suggests that without other
priming mechanisms to either decrease the Ka,3D/Ka,2D0 ratio
or increase mr, FcR-mediated leukocyte adhesion to targets
(e.g., opsonized bacteria or immune complex deposited on
vessel walls) would be a rare occurrence, even for ml as high
as 1000 sites/	m2.
Soluble P-selectin is present in human plasma at a con-
centration of 30–300 ng/ml (0.2–2 nM) in healthy subjects
and severalfold higher in patients with thrombotic disorders
(Dunlop et al., 1992; Katayama et al., 1993; Ushiyama et
al., 1993; Chong et al., 1994). These are at least two orders
of magnitude lower than the Kd,3D (300–550 nM) for
PSGL-1, the only high-affinity ligand on leukocytes for
P-selectin. Such low circulating concentrations would not
be able to competitively inhibit the PSGL-1-mediated bind-
ing of leukocytes to P-selectin-expressing cells such as
platelets and vascular endothelial cells. It should be empha-
sized that this prediction does not exclude other possible
regulatory roles of soluble P-selectin. Similarly, while sol-
uble CD16 exists in circulation, the concentration (2.7 	g/
ml; Mathiot et al., 1993) is 30 times lower than its Kd,3D
for hIgG. If soluble CD16 could only serve an adhesion
antagonist role, our model predicts a minimal effect for it in
blocking CD16/hIgG-mediated adhesion. These examples
illustrate the usefulness of Eqs. 7–10 in analyzing situations
that involve 2D/3D competition binding.
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